Patient materials for Shire’s ADHD drug Intuniv presented unsubstantiated effectiveness and superiority claims and downplayed important risk info, said the FDA’s Division of Drug Marketing, ...
Shire announced an FDA approval for Intuniv (guanfacine) Extended Release Tablets yesterday, and is preparing professional advertising efforts for a November launch. Matthew Cabrey, a spokesperson for ...
The FDA's approval of Intuniv brings to four the number of drugs for ADHD currently marketed by Shire. (The other three are Adderall XR, Vyvanse and the Daytrana patch.) There are about 11 drugs on ...
Intuniv is available as 1mg, 2mg, 3mg, and 4mg extended-release tablets The Food and Drug Administration (FDA) has approved a new update to the Intuniv (guanfacine; Shire) labeling regarding ...
NEW ORLEANS, May 21 /PRNewswire-FirstCall/ --Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced new findings on once ...
Shire faces a delay in getting its new attention-deficit hyperactivity disorder drug Intuniv approved in the USA but the company is still confident of launching the treatment across the pond before ...
Data from a Phase III study evaluating Shire’s Intuniv in Japan in adults with attention deficit hyperactivity disorder indicate that the drug could improve symptoms of the condition in this patient ...
Teva Pharmaceutical Industries Ltd is seeking to disqualify two expert witnesses hired by plaintiffs who are accusing one of the drugmaker's units of illegally delaying the release of a generic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback